Ordinary Adjustment | Solactive China Healthcare Disruption Index | Effective Date 2nd March 2026
Solactive China Healthcare Disruption Index:
In the ordinary adjustment, the following composition will be implemented effective open 2nd March 2026:
| AB&B BIO-TECH-B ORD H |
| ABBISKO CAYMAN LTD |
| AKESO INC |
| ALIBABA HEALTH INFORMATION TECHNOLOGY LTD |
| ALPHAMAB ONCOLOGY |
| ASCLETIS PHARMA INC |
| BIOCYTOGEN PHARMACEUTICALS-H |
| CHINA MEDICAL SYSTEM HOLDINGS LTD |
| CHINA RESOURCES PHARMACEUTICAL |
| CSPC PHARMACEUTICAL GROUP LTD |
| CSTONE PHARMACEUTICALS |
| DUALITYBIO-B ORD |
| EVEREST MEDICINES LTD |
| GENFLEET-B ORD H |
| GENSCRIPT BIOTECH CORP |
| GRAND PHARMACEUTICAL GROUP LTD |
| HAIXI PHARMA ORD H |
| HANSOH PHARMACEUTICAL GROUP CO |
| HBM HOLDINGS LTD |
| HENGRUI PHARMA ORD H |
| HUTCHMED CHINA LTD |
| INNOVENT BIOLOGICS INC |
| INSILICO ORD |
| JACOBIO PHARMACEUTICALS GROUP CO LTD |
| JINHAI INTERNATIONAL GROUP HOLDINGS LTD |
| KEYMED BIOSCIENCES INC |
| LEADS BIOLABS-B ORD H |
| LEPU BIOPHARMA CO LTD-H |
| LIVZON PHARMACEUTICAL GROUP INC |
| LUYE PHARMA GROUP LTD |
| MEDLIVE TECHNOLOGY CO LTD |
| PHARMARON BEIJING CO LTD-H |
| REMEGEN CO LTD-H |
| SHANDONG BOAN BIOTECHNOLOGY CO LTD |
| SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD |
| SHANGHAI HENLIUS BIOTECH INC |
| SHANGHAI JUNSHI BIOSCIENCES CO LTD |
| SHANGHAI MICROPORT MEDBOT GR |
| SHANGHAI PHARMACEUTICALS HOLDING CO LTD-H |
| SIHUAN PHARMACEUTICAL HLDGS GRP ORD |
| SIMCERE PHARMACEUTICAL GROUP |
| SINO BIOPHARMACEUTICAL LTD ORD |
| SKB BIO-B ORD H |
| SUNSHINE LAKE PHARMA CO LTD |
| TOT BIOPHARM INTERNATIONAL CO LTD |
| TRANSTHERA-B ORD H |
| TYK MEDICINES-B ORD H |
| VIGONVITA-B ORD H |
| WUXI APPTEC CO LTD |
| WUXI BIOLOGICS CAYMAN INC |
| XTALPI HOLDINGS LTD |
| ZAI LAB LTD |